EUVIMEDEUVIMED entdecken
Crossref

Network Pharmacology and Molecular Simulations Identify AURKA and CDK1 as Potential Targets of 20(S)-Rg3 in Prostate Cancer

Zien Yu, Yanzhen Li, Chi Huang, Mingyu Wei, Shaojie Ma, Xiujun Wang, Chunluan Yuan

Journal of Computational Biophysics and Chemistry · 2027-03 · 26 (03) · 741-760

DOI: 10.1142/s2737416526500730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Computational Biophysics and Chemistry, online erschienen am 16.04.2026. Verfasst von Zien Yu und 6 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Open-end Funds of Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, XZHMU-QL Joint Research Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study employed network pharmacology, bioinformatics and Molecular Dynamics (MD) simulations methods to elucidate the anti-prostate cancer mechanism of 20(S)-Rg3. By integrating four databases, 451 potential drug targets were identified and cross-analyzed with 14,886 prostate cancer-related genes (GeneCards), 2906 Weighted Correlation Network Analysis (WGCNA) module genes and 4515 DepMap essential genes, ultimately yielding 22 common targets. Functional enrichment analysis indicated that these genes were mainly involved in cell-cycle regulation. Transcriptomic analysis of the TCGA-PRAD cohort confirmed that the core targets AURKA and CDK1 were significantly overexpressed in prostate cancer. Survival analysis demonstrated that high expression of AURKA and CDK1 was associated with shorter Progression-Free Survival (PFS) and reduced Disease-Free Survival (DFS). In prostate cancer cell lines, CRISPR dependency scores below −1 suggested their essential roles. Analysis of 400 ns MD simulations showed that 20(S)-Rg3 binds to the core targets with binding energies of −33.47 kcal/mol (AURKA) and −33.51 kcal/mol (CDK1), comparable to co-crystal inhibitors and exhibits stable Root Mean Square Deviation (RMSD [Formula: see text] 2–3 Å) with persistent hydrogen–bond interactions (6–9 per frame). These quantitative findings indicate that 20(S)-Rg3 may exert anticancer effects in prostate cancer by selectively targeting AURKA and CDK1 to inhibit cell-cycle progression, thereby providing a numerical and mechanistic basis for its antitumor activity.

Förderung

  • National Natural Science Foundation of China
  • Open-end Funds of Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening
  • XZHMU-QL Joint Research Fund
  • Lianyungang Municipal Health Technology Project
  • Lianyungang 521 Project Research Fund
  • Beijing Science and Technology Innovation Medical Development Foundation

Zitieren

APA

Yu, Z., Li, Y., Huang, C., Wei, M., Ma, S., Wang, X., & Yuan, C. (2027). Network Pharmacology and Molecular Simulations Identify AURKA and CDK1 as Potential Targets of 20(S)-Rg3 in Prostate Cancer. Journal of Computational Biophysics and Chemistry, 26(03), 741-760. https://doi.org/10.1142/s2737416526500730

Vancouver

Yu Z, Li Y, Huang C, Wei M, Ma S, Wang X, et al. Network Pharmacology and Molecular Simulations Identify AURKA and CDK1 as Potential Targets of 20(S)-Rg3 in Prostate Cancer. Journal of Computational Biophysics and Chemistry. 2027;26(03):741-760. doi:10.1142/s2737416526500730

BibTeX
@article{Yu2027,
  author = {Yu, Zien and Li, Yanzhen and Huang, Chi and Wei, Mingyu and Ma, Shaojie and Wang, Xiujun and Yuan, Chunluan},
  title = {Network Pharmacology and Molecular Simulations Identify AURKA and CDK1 as Potential Targets of 20(S)-Rg3 in Prostate Cancer},
  journal = {Journal of Computational Biophysics and Chemistry},
  year = {2027},
  volume = {26},
  number = {03},
  pages = {741--760},
  doi = {10.1142/s2737416526500730}
}
Kostenlos starten →